Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Nabriva Therapeutics AG (NBRV : NSDQ)

• Company Description    Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics' medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics' lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP). Number of Employees: 73

• Price / Volume Information    Yesterday's Closing Price: $0.19 Daily Weekly Monthly 20 Day Moving Average: 643,634 shares Shares Outstanding: 632.05 (millions) Market Capitalization: $122.11 (millions) Beta: 1.57 52 Week High: $1.57 52 Week Low: $0.19 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -41.46% -35.90% 12 Week -58.63% -53.51% Year To Date -67.74% -60.59%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 25-28 NORTH WALL QUAY IFSC - DUBLIN,L2 19406 IRL ph: 353-1649-2000 fax: 610-816-6639 david.garrett@nabriva.com http://www.nabriva.com

• General Corporate Information    Officers Theodore Schroeder - Chief Executive Officer and Director Daniel Burgess - Chairman Daniel Dolan - Chief Financial Officer Steven Gelone - President; Chief Operating Officer and Director Colin Broom - Director Peer Information Nabriva Therapeutics AG (CORR.) Nabriva Therapeutics AG (RSPI) Nabriva Therapeutics AG (CGXP) Nabriva Therapeutics AG (BGEN) Nabriva Therapeutics AG (GTBP) Nabriva Therapeutics AG (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G63637113 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 632.05 Most Recent Split Date: 12.00 (0.10:1) Beta: 1.57 Market Capitalization: $122.11 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.19 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.73 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.67 Price/Cash Flow: - Price / Sales: 3.55 EPS Growth vs. Year Ago Period: 62.26% vs. Previous Quarter: 16.67% Sales Growth vs. Year Ago Period: 217.12% vs. Previous Quarter: -13.40% ROE 03/31/22 - -82.07 12/31/21 - -82.13 09/30/21 - -98.31 ROA 03/31/22 - -57.11 12/31/21 - -57.36 09/30/21 - -67.28 Current Ratio 03/31/22 - 4.01 12/31/21 - 3.59 09/30/21 - 4.48 Quick Ratio 03/31/22 - 3.05 12/31/21 - 2.94 09/30/21 - 3.69 Operating Margin 03/31/22 - -137.52 12/31/21 - -171.14 09/30/21 - -245.41 Net Margin 03/31/22 - -137.52 12/31/21 - -171.14 09/30/21 - -245.41 Pre-Tax Margin 03/31/22 - -135.62 12/31/21 - -169.44 09/30/21 - -243.21 Book Value 03/31/22 - 0.07 12/31/21 - 0.09 09/30/21 - 0.12 Inventory Turnover 03/31/22 - 1.18 12/31/21 - 1.07 09/30/21 - 0.81 Debt-to-Equity 03/31/22 - 0.09 12/31/21 - 0.08 09/30/21 - 0.08 Debt-to-Capital 03/31/22 - 8.07 12/31/21 - 7.40 09/30/21 - 7.55

Powered by Zacks Investment Research ©